Ignite Creation Date:
2024-05-05 @ 11:11 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01275222
Status:
COMPLETED
Last Update Posted:
2021-06-25
First Post:
2011-01-10
Brief Title:
Everolimus in Combination With Imatinib in Patients With Glivec RefractoryResistant Gastrointestinal Stromal Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Gastrointestinal Stromal Tumors |
Keywords:
| Name | View |
|---|---|
| digestive system cancer | View |
| RAD001 | View |
| everolimusGIST | View |
| everolimus | View |
| mTOR | View |
| Imatinib resistant | View |
| Imatinib-refractoryresistant | View |
| gastrointestinal stromal tumors | View |
| Gastrointestinal Stromal TumorsGIST | View |
| soft tissue sarcoma | View |
| stomach tumor | View |
| tumor of interstitial cells of Cajal ICC | View |